Research & Literature

Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.

Vose JM

American journal of hematology 2015; (90(8)):739-45 doi:10.1002/ajh.24094.

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.

Hoster E, Rosenwald A, Berger F, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(12)):1386-94 doi:10.1200/JCO.2015.63.8387.

Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year.

Herrero-Vicent C, Machado I, Illueca C, et al.

Ecancermedicalscience 2016; (10()):627 doi:10.3332/ecancer.2016.627.

Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.

Tucker DL, Naylor G, Kruger A, et al.

British journal of haematology 2017; (178(2)):327-329 doi:10.1111/bjh.14122.

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

Hermine O, Hoster E, Walewski J, et al.

Lancet (London, England) 2016; (388(10044)):565-75.

Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage.

Queirós AC, Beekman R, Vilarrasa-Blasi R, et al.

Cancer cell 2016; (30(5)):806-821 doi:10.1016/j.ccell.2016.09.014.

Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.

Vose JM

American journal of hematology 2017; (92(8)):806-813 doi:10.1002/ajh.24797.

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

Le Gouill S, Thieblemont C, Oberic L, et al.

The New England journal of medicine 2017; (377(13)):1250-1260 doi:10.1056/NEJMoa1701769.

CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course.

Hu Z, Sun Y, Schlette EJ, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018; (31(2)):327-336 doi:10.1038/modpathol.2017.135.

Smoldering mantle cell lymphoma.

Ye H, Desai A, Zeng D, et al.

Journal of experimental & clinical cancer research : CR 2017; (36(1)):185 doi:10.1186/s13046-017-0652-8.

Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.

Greenwell IB, Staton AD, Lee MJ, et al.

Cancer 2018; (124(11)):2306-2315 doi:10.1002/cncr.31328.

t(11;14)-positive mantle cell lymphomas lacking cyclin D1 (CCND1) immunostaining because of a CCND1 mutation or exclusive expression of the CCND1b isoform.

Iaccarino I, Afify L, Aukema SM, et al.

Haematologica 2018; (103(9)):e432-e435 doi:10.3324/haematol.2018.192435.

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.

Eskelund CW, Albertsson-Lindblad A, Kolstad A, et al.

Haematologica 2018; (103(11)):e541-e543 doi:10.3324/haematol.2018.194399.

Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis.

Hilal T, Wang Z, Almader-Douglas D, et al.

American journal of hematology 2018; (93(10)):1220-1226 doi:10.1002/ajh.25226.

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.

Eyre TA, Walter HS, Iyengar S, et al.

Haematologica 2019; (104(2)):e68-e71 doi:10.3324/haematol.2018.198812.

Mantle cell lymphoma with involvement of the digestive tract.

Oña-Ortiz FM, Sánchez-Del Monte J, Ramírez-Solís ME, et al.

Revista de gastroenterologia de Mexico (English) 2019; (84(4)):434-441 doi:10.1016/j.rgmx.2018.07.001.

Gastrointestinal Involvement in Patients with Mantle Cell Lymphoma: A Single Center Experience of Eighty-Five Patients.

Lamm W, Dolak W, Kiesewetter B, et al.

Digestive diseases (Basel, Switzerland) 2019; (37(3)):194-200 doi:10.1159/000496508.

SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients.

Xu J, Wang L, Li J, et al.

The American journal of surgical pathology 2019; (43(5)):710-716 doi:10.1097/PAS.0000000000001233.

Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.

Owen C, Berinstein NL, Christofides A, Sehn LH

Current oncology (Toronto, Ont.) 2019; (26(2)):e233-e240 doi:10.3747/co.26.4345.

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.

Jeon YW, Yoon S, Min GJ, et al.

Cancer medicine 2019; (8(16)):6860-6870 doi:10.1002/cam4.2565.

Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.

Kluin-Nelemans HC, Hoster E, Hermine O, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(3)):248-256 doi:10.1200/JCO.19.01294.

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

Wang M, Munoz J, Goy A, et al.

The New England journal of medicine 2020; (382(14)):1331-1342 doi:10.1056/NEJMoa1914347.

Molecular Pathogenesis of Mantle Cell Lymphoma.

Navarro A, Beà S, Jares P, Campo E

Hematology/oncology clinics of North America 2020; (34(5)):795-807 doi:10.1016/j.hoc.2020.05.002.

From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later.

Fang H, Medeiros LJ, Tang Z, et al.

Annals of diagnostic pathology 2021; (50()):151649 doi:10.1016/j.anndiagpath.2020.151649.

Multiple lymphomatous polyposis: A presentation for mantle cell lymphoma.

Gallivan C, Akbar A

Clinical case reports 2020; (8(12)):3038-3042 doi:10.1002/ccr3.3291.

Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management.

Isaac KM, Portell CA, Williams ME

Current oncology reports 2021; (23(9)):102 doi:10.1007/s11912-021-01094-y.

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.

Tam CS, Dimopoulos M, Garcia-Sanz R, et al.

Blood advances 2022; (6(4)):1296-1308 doi:10.1182/bloodadvances.2021005621.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With Secondary Acquisition of t(11;14)(q13;q32)/CCND1-IGH: A Rare Variant Of Richter Transformation to Mantle Cell Lymphoma.

Zhao Y, McCracken J, Rehder C, Wang E

Clinical lymphoma, myeloma & leukemia 2022; (22(5)):e310-e313 doi:10.1016/j.clml.2021.10.017.

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.

Giné E, de la Cruz F, Jiménez Ubieto A, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(11)):1196-1205 doi:10.1200/JCO.21.02321.

Stem cell transplant for mantle cell lymphoma in Taiwan.

Wang YH, Hsieh CY, Hsiao LT, et al.

Scientific reports 2022; (12(1)):5662 doi:10.1038/s41598-022-09539-5.

New Directions for Mantle Cell Lymphoma in 2022.

Kumar A, Eyre TA, Lewis KL, et al.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2022; (42()):1-15 doi:10.1200/EDBK_349509.

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.

Wang ML, Jurczak W, Jerkeman M, et al.

The New England journal of medicine 2022; (386(26)):2482-2494 doi:10.1056/NEJMoa2201817.

Mantle cell lymphoma negative for t(11,14) involving the kidneys: a case report.

Nassereldine H, Mohty R, Awada H, et al.

Journal of medical case reports 2022; (16(1)):254 doi:10.1186/s13256-022-03470-z.

Mantle cell lymphoma treatment options for elderly/unfit patients: A systematic review.

Alnassfan T, Cox-Pridmore MJ, Taktak A, Till KJ

EJHaem 2022; (3(1)):276-290 doi:10.1002/jha2.311.

Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.

Heini AD, Bacher U, Porret N, et al.

Cells 2022; (11(17)) doi:10.3390/cells11172747.

BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.

Eyre TA, Shah NN, Dreyling M, et al.

Future oncology (London, England) 2022; (18(36)):3961-3969 doi:10.2217/fon-2022-0976.

Central nervous system involvement by mantle cell lymphoma.

McLaughlin N, Wang Y, Witzig T, et al.

Leukemia & lymphoma 2023; (64(2)):371-377 doi:10.1080/10428194.2022.2148211.

Bone marrow infiltration by Non-Hodgkin lymphoma: An experience in a tertiary care centre.

Suhail M, Mahmood A, Mahmood R, et al.

JPMA. The Journal of the Pakistan Medical Association 2023; (73(3)):558-561 doi:10.47391/JPMA.6730.

CAR T-Cell therapy for the management of mantle cell lymphoma.

Huang Z, Chavda VP, Bezbaruah R, et al.

Molecular cancer 2023; (22(1)):67 doi:10.1186/s12943-023-01755-5.

CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.

Park JH, Nath K, Devlin SM, et al.

Nature medicine 2023; (29(7)):1710-1717 doi:10.1038/s41591-023-02404-6.

Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease.

Lew TE, Cliff ERS, Dickinson M, et al.

Leukemia & lymphoma 2023; (64(11)):1792-1800 doi:10.1080/10428194.2023.2241095.

Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.

De SK

Current medicinal chemistry 2024; (31(30)):4757-4762 doi:10.2174/0109298673251030231004052822.

SOX11+ Large B-Cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma?

Li S, Tang G, Jain P, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2024; (37(2)):100405 doi:10.1016/j.modpat.2023.100405.

Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma.

Lu J, Do B, Primeaux B

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2025; (31(2)):230-235 doi:10.1177/10781552241232331.

Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions.

Gallucci Figorelle L, Galvão PT, de Lima FMR, et al.

Clinical lymphoma, myeloma & leukemia 2024; (24(7)):433-445 doi:10.1016/j.clml.2024.03.010.

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.

Dreyling M, Doorduijn J, Giné E, et al.

Lancet (London, England) 2024; (403(10441)):2293-2306 doi:10.1016/S0140-6736(24)00184-3.

Mantle cell lymphoma characterized by numerous diffuse polypoid lesions along the entire digestive tract: A case report.

Cheng S, Yang L, Wang X

Oncology letters 2024; (28(2)):363 doi:10.3892/ol.2024.14496.

Treatment of relapsed/refractory MCL.

Silkenstedt E, Dreyling M

Blood 2025; (145(7)):673-682 doi:10.1182/blood.2023022353.

Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma.

Wang JF, Wang Y

Expert review of hematology 2024; (17(10)):651-659 doi:10.1080/17474086.2024.2389993.

Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma.

Cai L, Roos J, Miranda PAP, et al.

Journal of medical economics 2024; (27(1)):1552-1557 doi:10.1080/13696998.2024.2422227.

A rapid progression from classical mantle cell lymphoma to a blastoid variant.

Chiriac R, Donzel M, Baseggio L

Leukemia research reports 2024; (22()):100484 doi:10.1016/j.lrr.2024.100484.

To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL.

Silkenstedt E, Dreyling M

Hematology. American Society of Hematology. Education Program 2024; (2024(1)):42-47 doi:10.1182/hematology.2024000546.

Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

Wang M, Jurczak W, Trneny M, et al.

The Lancet. Oncology 2025; (26(2)):200-213 doi:10.1016/S1470-2045(24)00682-X.

Clinical outcomes and therapeutic modalities in older Chinese patients with MCL: a multi-center real-world retrospective study.

Yang Y, Yang P, Zhang W, et al.

Annals of medicine 2025; (57(1)):2482013 doi:10.1080/07853890.2025.2482013.

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.

Wang M, Salek D, Belada D, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(20)):2276-2284 doi:10.1200/JCO-25-00690.

Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE.

Mishima Y, Hashimoto D, Ichii M, et al.

Annals of hematology 2025; (104(9)):4605-4610 doi:10.1007/s00277-025-06569-7.

Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma.

Sharma S, Ali R, Bouska A, et al.

Nature communications 2025; (16(1)):9762 doi:10.1038/s41467-025-64666-7.

Managing Treatment-Emergent Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CAR-T Cell Therapy: A Case-Based Review of the use of Emapalumab.

Donzelli L, Zullino V, Torelli GF, et al.

Hematological oncology 2026; (44(1)):e70157 doi:10.1002/hon.70157.

TP53 Mutations in Mantle Cell Lymphoma: From Backup to Game Changer.

Carazzolo ME, Moioli A, Visco C

Journal of clinical medicine 2025; (14(23)) doi:10.3390/jcm14238480.